




RealRate

PHARMACEUTICAL 2020

Lixte Biotechnology Holdings INC
Rank 117 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 129% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is 300%, being 62% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	2,672
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	238
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	50
Other Revenues	0
Property and Equipment	0
Research and Development	821
Selling, General and Administrative Expense	1,669

Output Variable	Value in 1000 USD
Assets	2,672
Liabilities	238
Expenses	2,490
Revenues	0
Stockholders Equity	2,434
Net Income	-2,440
Comprehensive Net Income	-2,440
BaseVar	2,725
ECR before Limited Liability	197%
Economic Capital Ratio	300%